Top

Graefe's Archive for Clinical and Experimental Ophthalmology

Published in:

01-10-2007 | Laboratory Investigation

Inhibition of corneal angiogenesis by ascorbic acid in the rat model

Authors: Gholam A. Peyman, Muhamet Kivilcim, Ana Munoz Morales, John T. DellaCroce, Mandi D. Conway

Published in: Graefe's Archive for Clinical and Experimental Ophthalmology | Issue 10/2007

Abstract

Purpose

To evaluate the effect of topically administered ascorbic acid on experimentally induced corneal neovascularization in the rat model.

Materials and methods

Corneal chemical cauterization of 72 eyes in Long-Evans male rats was performed using silver nitrate/potassium nitrate sticks. Nine groups of eight eyes were used to evaluate eight concentrations of ascorbic acid with one group of eight eyes serving as a control. Topical instillation of 100 mg/ml non-pH-neutralized ascorbic acid was performed in one group while the remaining seven groups were evaluated using pH-neutralized ascorbic acid in concentrations of 100 mg/ml, 50 mg/ml, 10 mg/ml, 5 mg/ml, 1 mg/ml, 500 µg/ml, and 250 µg/ml.

Results

The percentage of corneal neovascularization and burn stimulus score was determined for all the eyes. The means of percent of corneal neovascularization in ascorbic acid 100 mg/ml (non-neutralized), 100 mg/ml, 50 mg/ml, 10 mg/ml, 5 mg/ml, 1 mg/ml, 500 μg/ml, 250 μg/ml, and control group were 17.50 ± 12.80 (p = 0.001), 17.00 ± 19.30 (p = 0.001), 15.25 ± 13.26 (p = 0.001), 17.62 ± 11.89 (p = 0.001), 28.87 ± 23.08 (p = 0.001), 29.62 ± 16.91 (p = 0.001), 60.12 ± 8.50 (p = 0.04), 65.62 ± 2.26 (p = 0.185), and 68.25 ± 4.06, respectively (Tables 1 and 2). All animals had a burn score of 2+ or higher (Table 1).

Conclusion

Ascorbic acid applied in a topical solution appears to inhibit corneal neovascularization in the rat model of inflammatory neovascularization in concentrations in a dose-dependent manner. The optimal dose-effect relation was in our model found in concentrations between 1 mg and 500 µg/ml. At concentrations below 500 µg/ml there was no statistically significant inhibition in the degree of corneal neovascularization compared to control.

Wu PC, Yang LC, Kuo HK et al (2005) Inhibition of corneal angiogenesis by local application of vasostatin. Mol Vis 11:28–35PubMed

Chang JH, Gabiason EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249PubMedCrossRef

Hill JC, Maske R (1988) An animal model for corneal graft rejection in high-risk keratoplasty. Transplantation 46:26–30PubMedCrossRef

Benelli U, Ross JR, Nardi M et al (1997) Corneal neovascularization induced by xenografts or chemical cautery inhibition by cyclosporin A. Investig Ophthalmol Vis Sci 38(2):274–281

Bocci G, Danesi R, Benelli U et al (1999) Inhibitory effect of suramin in rat models of angiogenesis in vitro and in vivo. Cancer Chemother Pharmacol 43:205–212PubMedCrossRef

Benelli U, Bocci G, Danesi R et al (1998) The heparan sulfate suleparoide inhibits rat corneal angiogenesis and in vitro neovascularization. Exp Eye Res 67:133–142PubMedCrossRef

D’Amato RJ, Loughnan MS, Flynn E et al (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91(9):4082–4085PubMedCrossRef

Fotsis T, Pepper M, Adlercreutz H et al (1993) Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90(7):2690–2694PubMedCrossRef

Hanashima C, Namiki H (1999) Reduced viability of vascular endothelial cells by high concentration of ascorbic acid in vitreous humor. Cell Biol Int 23(4):287–297PubMedCrossRef

10.

Bohmer JA, Sellhaus B, Schrage NF (2001) Effects of ascorbic acid on retinal pigment epithelial cells. Curr Eye Res 23(3):206–214PubMedCrossRef

11.

Takano S, Ishiwata S, Nakazawa M et al (1997) Determination of ascorbic acid in human vitreous humor by high-performance liquid chromatography with UV detection. Curr Eye Res 16(6):589–594PubMedCrossRef

12.

Ashino H, Shimamura M, Nakajima H et al (2003) Novel function of ascorbic acid as an angiostatic factor. Angiogenesis 6(4):259–269PubMedCrossRef

13.

Roomi MW, Ivanov V, Kalinovsky T et al (2005) In vivo antitumor effect of ascorbic acid, lysine, proline and green tea extract on human prostate cancer PC-3 xenografts in nude mice: evaluation of tumor growth and immunohistochemistry. In Vivo 19(1):179–183PubMed

14.

Connolly DT, Heuvelman DM, Nelson R et al (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84(5):1470–1478PubMed

15.

Cho A, Reidy MA (2002) Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 91(9):845–851PubMedCrossRef

16.

Johnson C, Galis ZS (2004) Matrix metalloproteinase-2 and -9 differentially regulate smooth muscle cell migration and cell-mediated collagen organization. Arterioscler Thromb Vasc Biol 24(1):54–60PubMedCrossRef

17.

Gurer G, Erdem S, Kocaefe C et al (2004) Expression of matrix metalloproteinases in vasculitic neuropathy. Rheumatol Int 24(5):255–259PubMedCrossRef

18.

Ferroni P, Basili S, Martini F et al (2003) Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med 51(5):295–300PubMedCrossRef

19.

Sung HJ, Johnson CE, Lessner SM et al (2005) Matrix metalloproteinase 9 facilitates collagen remodeling and angiogenesis for vascular constructs. Tissue Eng 11(1–2):267–276PubMedCrossRef

20.

Roomi MW, Ivanov V, Kalinovsky T et al (2005) In vitro and in vivo antitumorigenic activity of a mixture of lysine, proline, ascorbic acid, and green tea extract on human breast cancer lines MDA-MB-231 and MCF-7. Med Oncol 22(2):129–138PubMedCrossRef

21.

Knowles HJ, Raval RR, Harris AL et al (2003) Effect of ascorbate on the activity of hypoxia-inducible factor in cancer cells. Cancer Res 63:1764–1768PubMed

22.

Marinacci B (1994) Linus Pauling-In Memoriam. Linus Pauling Institute of Science and Medicine, Oregon State University, Corvallis, OR

23.

Sauberlich HE (1994) Pharmacology of vitamin C. Annu Rev Nutr 14:371–391PubMedCrossRef

24.

Brauchle M, Funk JO, Kind P et al (1996) Ultraviolet B and H2O2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J Biol Chem 271(36):21793–21797PubMedCrossRef

25.

Kuroki M, Voest EE, Amano S et al (1996) Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J Clin Invest 98(7):1667–1675PubMedCrossRef

26.

Ivanov VO, Ivanova SV, Niedzwiecki A (1997) Ascorbate affects proliferation of guinea-pig vascular smooth muscle cells by direct and extracellular matrix-mediated effects. J Mol Cell Cardiol 29(12):3293–3303PubMedCrossRef

27.

Joussen AM, Rohrschneider K, Reichling J et al (2000) Treatment of corneal neovascularization with dietary isoflavonoids and flavonoids. Exp Eye Res 71(5):483–487PubMedCrossRef

28.

Anderson MT, Staal FJ, Gitler C et al (1994) Separation of oxidant-initiated and redox-regulated steps in the NF-kappa B signal transduction pathway. Proc Natl Acad Sci USA 91(24):11527–11531PubMedCrossRef

29.

Bowie AG, O’Neill LA (2000) Vitamin C inhibits NF-kappa B activation by TNF via the activation of p38 mitogen-activated protein kinase. J Immunol 165(12):7180–7188PubMed

30.

Shono T, Ono M, Izumi H et al (1996) Involvement of the transcription factor NF-kappaB in tubular morphogenesis of human microvascular endothelial cells by oxidative stress. Mol Cell Biol 16(8):4231–4239PubMed

31.

Carcamo JM, Pedraza A, Borquez-Ojeda O et al (2002) Vitamin C suppresses TNF alpha-induced NF kappa B activation by inhibiting I kappa B alpha phosphorylation. Biochemistry 41(43):12995–13002PubMedCrossRef

32.

Ingber D, Folkman J (1988) Inhibition of angiogenesis through modulation of collagen metabolism. Lab Invest 59(1):44–51PubMed

33.

Nicosia RF, Belser P, Bonanno E et al (1991) Regulation of angiogenesis in vitro by collagen metabolism. In Vitro Cell Dev Biol 27A(12):961–966PubMedCrossRef

34.

Schnaper HW, Grant DS, Stetler-Stevenson WG et al (1993) Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 156(2):235–246PubMedCrossRef

35.

Schwartz E, Bienkowski RS, Coltoff-Schiller B et al (1982) Changes in the components of extracellular matrix and in growth properties of cultured aortic smooth muscle cells upon ascorbate feeding. J Cell Biol 92(2):462–470PubMedCrossRef

36.

Phillips GD, Stone AM, Jones BD et al (1994) Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo 8(6):961–965PubMed

37.

Amano S, Rohan R, Kuroki M et al (1998) Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci 39(1):18–22PubMed

38.

Philipp W, Speicher L, Humpel C (2000) Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci 41(9):2514–2522PubMed

39.

Cursiefen C, Rummelt C, Kuchle M (2000) Immunohistochemical localization of vascular endothelial growth factor, transforming growth factor alpha, and transforming growth factor beta1 in human corneas with neovascularization. Cornea 19(4):526–533PubMedCrossRef

40.

Orbe J, Rodriguez JA, Arias R et al (2003) Antioxidant vitamins increase the collagen content and reduce MMP-1 in a porcine model of atherosclerosis: implications for plaque stabilization. Atherosclerosis 167(1):45–53PubMedCrossRef

41.

Mahoney JM, Waterbury LD (1985) Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res 4:531–535PubMed

Title: Inhibition of corneal angiogenesis by ascorbic acid in the rat model
Authors: Gholam A. Peyman
Muhamet Kivilcim
Ana Munoz Morales
John T. DellaCroce
Mandi D. Conway
Publication date: 01-10-2007
Publisher: Springer-Verlag
Published in: Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 10/2007
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI: https://doi.org/10.1007/s00417-007-0542-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Inhibition of corneal angiogenesis by ascorbic acid in the rat model

Abstract

Purpose

Materials and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2007

Photodynamic therapy for recurrent hyphema after proton beam radiotherapy of iris melanoma

Evaluation of phosphenes elicited by extraocular stimulation in normals and by suprachoroidal-transretinal stimulation in patients with retinitis pigmentosa

The consequences of delayed intervention when treating chemical eye burns

Epidermal growth factor inhibits glycogen synthase kinase-3 (GSK-3) and β-catenin transcription in cultured ARPE-19 cells

Electron microscopic findings in levator muscle biopsies of patients with isolated congenital or acquired ptosis

Combined grading for choroidal neovascularisation: colour, fluorescein angiography and autofluorescence images